Navigation Links
PET scans may allow early prediction of response to targeted therapy of thyroid cancer
Date:2/1/2011

Reston, Va. (February 1, 2011) Positron emission tomography (PET) can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine. Currently being tested in clinical trials, vandetanib inhibits the function of the RET (rearranged-during-transfection protein) proto-oncogene and other protein kinases involved in the development and progression of cancer.

"For the most part, clinical trials have been measuring the effectiveness of vandetanib by changes in tumor size. Based on the activating effects of mutated RET and other protein kinases on numerous intracellular metabolic pathways, we hypothesized that PET imaging could play a role in the early evaluation of response to vandetanib," said Martin A. Walter, MD, lead author of the study "Metabolic Imaging Allows Early Prediction of Response to Vandetanib."

The study examined the usefulness of metabolic imaging to determine response to vandetanib in three ways. First, medullary thyroid cancer cells were used to create an in vitro model. After cultivation, the cells were treated with vandetanib, and changes in the metabolic profile of the cells were successfully monitored by transcriptional profiling and by radiotracer uptake studies.

Using the same untreated cells, the researchers then created an in vivo model by injecting mice with the cancerous cells and treating them with vandetanib. Small animal PET/computed tomography (CT) imaging was performed and was found to reproduce the in vitro findings of metabolic activity after three days.

Finally, a 43-year old patient with biopsy-proven metastasized medullary thyroid cancer was treated with vandetanib. PET scans taken at 12 and 24 weeks after treatment were able to detect metabolic response to vandetanib, consistent with the in vitro and in vivo samples.

"With the increasing number of available treatment options, careful patient selection is necessary to ensure targeted therapy is administered to those most likely to gain clinical benefit," said Walter. "The identification of markers of treatment efficacy is a key factor for the success of these novel treatment approaches."

"Furthermore," he continued, "relating in-vivo PET imaging metabolic data with transcriptional profiling data using cluster analysis is an innovative concept that allows much potential in the field of molecular imaging."


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. FDA Seeks Reduction in Radiation From Medical Scans
2. New Heart CT Scans Deliver Far Less Radiation: Study
3. Scans Might Monitor Success of Alzheimers Drugs
4. Brain scans could be marketing tool of the future
5. Scans May Be Misleading for Hockey Players
6. Scans of brain networks may help predict injurys effects
7. CT and MRI scans associated with shorter hospital stays and decreased costs
8. Fear of getting fat seen in healthy womens brain scans
9. Researchers successfully lower radiation dose associated with pediatric chest CT scans
10. Summit aims to develop guidelines for safe and effective CT scans
11. Simple reduction technique decreases radiation dose associated with CT scans of the head
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... NY (PRWEB) , ... May 25, 2016 , ... ... and Florida International University (FIU) Herbert Wertheim College of Medicine announced the AUA-FIU ... Medical Doctor Degree and Global Health Certificate from AUA and a Certificate of ...
(Date:5/25/2016)... ... May 25, 2016 , ... Dr. Travis Schwarz is ... at 8618 Mexico Road, O’Fallon, MO 63366. He serves patients of all ages with ... treatments . Dr. Schwarz’s success is reflected in the superior patient reviews that he ...
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a leading ... 11 innovative workshops and training opportunities in the growing field of yoga ... individuals who are dealing with specific health issues—including injuries, illnesses, and temporary or chronic ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker Insurance Group has ... McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most successful agencies for ... all those who knew him. The award named for him is not given every ...
(Date:5/25/2016)... ... ... The Global Wellness Summit (GWS) today announced that its 2016 agenda will ... continent that pioneered the medical/wellness concept for the world. , Delegates to the 10th ... Henri Chenot, Founder of the Chenot Group, which operates wellness centers around the world ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/23/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... programs. The hands-on learning experience is a 12-week summer ... Fellowship and Internship programs bring ... and interns are provided optional housing free of charge ... at the Riverfront Residence Hall to foster communication and ...
(Date:5/23/2016)... Non-invasive diagnostic test realizes the potential of ... be presented at Yissum’s booth, at IATI-BIOMED 2016 conference  ... the Hebrew University of Jerusalem announced today it ... MKI, the technology investment arm of Morris Kahn , ... early detection of multiple diseases by analyzing circulating DNA ...
Breaking Medicine Technology: